Jason Zemansky's Stock Ratings

B of A Securities Analyst

Jason Zemansky is an analyst at B of A Securities. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 07/07/2024

Overall Average Return

17.3%

Smart Score

69.1%

Overall Average Return Percentile

76th

Number of Ratings

25
Buy NowGet Alert
07/05/2024INSMBuy Now
Insmed
$70.0518.49%$83 → $83MaintainsBuyGet Alert
06/28/2024INSMBuy Now
Insmed
$70.0518.49%$62 → $83MaintainsBuyGet Alert
06/20/2024ESPRBuy Now
Esperion Therapeutics
$2.404.17%$2.9 → $2.5DowngradeNeutral → UnderperformGet Alert
05/29/2024INSMBuy Now
Insmed
$70.05-11.49%$40 → $62MaintainsBuyGet Alert
05/28/2024INSMBuy Now
Insmed
$70.05-42.9%$40 → $40MaintainsBuyGet Alert
05/23/2024CYTKBuy Now
Cytokinetics
$56.675.88%$70 → $60MaintainsNeutralGet Alert
05/14/2024CYTKBuy Now
Cytokinetics
$56.6723.52%$75 → $70MaintainsNeutralGet Alert
12/26/2023ALVRBuy Now
AlloVir
$0.7238.31%$17 → $1DowngradeBuy → UnderperformGet Alert
10/25/2023SNDXBuy Now
Syndax Pharmaceuticals
$21.4934.95% → $29Initiates → BuyGet Alert
09/06/2023INSMBuy Now
Insmed
$70.05-47.18%$35 → $37MaintainsBuyGet Alert
09/05/2023RCUSBuy Now
Arcus Biosciences
$13.8466.18%$21 → $23MaintainsNeutralGet Alert
08/18/2023ALVRBuy Now
AlloVir
$0.722251.31% → $17Initiates → BuyGet Alert
08/11/2023KURABuy Now
Kura Oncology
$19.9955.08% → $31Initiates → BuyGet Alert
07/03/2023RPHMBuy Now
Reneo Pharmaceuticals
$1.471464.63% → $23Initiates → BuyGet Alert
06/15/2023ESPRBuy Now
Esperion Therapeutics
$2.4066.67%$1.25 → $4UpgradeUnderperform → BuyGet Alert
05/12/2023HOWLBuy Now
Werewolf Therapeutics
$2.18358.72%$9 → $10MaintainsBuyGet Alert
03/23/2023HOWLBuy Now
Werewolf Therapeutics
$2.18312.84% → $9ReiteratesBuy → BuyGet Alert
03/16/2023ESPRBuy Now
Esperion Therapeutics
$2.40-37.5%$8 → $1.5DowngradeNeutral → UnderperformGet Alert
02/27/2023ESPRBuy Now
Esperion Therapeutics
$2.40233.33% → $8Reinstates → NeutralGet Alert
02/17/2023CYTKBuy Now
Cytokinetics
$56.67-13.53% → $49Initiates → NeutralGet Alert
01/30/2023HOWLBuy Now
Werewolf Therapeutics
$2.18266.97%$9 → $8MaintainsBuyGet Alert
11/18/2022RCUSBuy Now
Arcus Biosciences
$13.84138.44% → $33Initiates → NeutralGet Alert
11/18/2022INSMBuy Now
Insmed
$70.05-44.33% → $39Initiates → BuyGet Alert
02/22/2022FIXXBuy Now
Homology Medicines
——$450 → $162MaintainsBuyGet Alert
12/13/2021ALLKBuy Now
Allakos
$0.7720119.15%—MaintainsBuyGet Alert

Recent Analyst Stock Rating News

Workday To Rally Over 52%? Here Are 10 Top Analyst Forecasts For Thursday
Cognizant Technology Solutions To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
AlloVir's RSV Therapy Is Underappreciated Gem, BofA Comments On Future Potential
B of A Securities analyst Jason Zemansky initiated coverage on AlloVir Inc (NASDAQ: ALVR) with a Buy rating and 
Verastem To Rally Around 287%? Here Are 10 Other Analyst Forecasts For Thursday
Piper Sandler boosted the price target for Accenture plc (NYSE: ACN) from $250 to $316. Piper Sandler analyst Arvind Ramnani upgraded the stock from Underweight to Neutral. Accenture shares rose 1.1% to $318.50 in pre-market trading.
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Are Secretly Monitoring But Not Talking About Yet
Investors are on the hunt for undervalued, underfollowed and emerging stocks when it comes to spotting opportunities. Retail traders have countless methods at their disposal to uncover new information.
Why Esperion Therapeutics Stock Is Tanking Thursday
Esperion Therapeutics Inc (NASDAQ: ESPR) shares are plummeting Thursday after the company reported a disagreement with one of its partners over certain milestone payments. 
Why BofA Turned Bullish On Checkmate Pharmaceuticals, But Slashed Price Target
Given the early clinical data on Checkmate Pharmaceuticals Inc’s (NASDAQ: CMPI) vidutolimod, key opinion leaders remain “positively biased on its outlook,” according to BofA Securities.
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.
Get Started for Free